Farther Finance Advisors’s Arbutus Biopharma ABUS Stock Holding History

Farther Finance Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-117	Closed	-$529	–	5976
2026 Q1	$529	Hold	117	–	–	﹤0.01%	5255
2025 Q4	$563	Sell	117 -139	-54%	-$625	﹤0.01%	5032
2025 Q3	$1.16K	Buy	+256	New	+$940	﹤0.01%	4323
2025 Q2	–	Sell	-266	Closed	-$926	–	4489
2025 Q1	$926	Sell	266 -7,734	-97%	-$25.8K	﹤0.01%	3633
2024 Q4	$26.2K	Hold	8,000	–	–	﹤0.01%	1970
2024 Q3	$30.8K	Hold	8,000	–	–	﹤0.01%	1887
2024 Q2	$25K	Hold	8,000	–	–	﹤0.01%	1709
2024 Q1	$20.5K	Buy	+8,000	New	+$20.7K	﹤0.01%	1485

Other funds holding ABUS

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

WMA

Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PPWP

Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Farther Finance Advisors's ABUS Position: Q2 2026 in Review

Farther Finance Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 117 shares — an estimated $529 sold.

Farther Finance Advisors first reported a position in ABUS in Q1 2024 and held it in 8 quarters. The position peaked at $30.8K in Q3 2024. 19 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Farther Finance Advisors reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
Farther Finance Advisors sold 117 Arbutus Biopharma shares in Q2 2026, an estimated $529.
Farther Finance Advisors first reported a position in Arbutus Biopharma in Q1 2024 and held it in 8 quarters.
Farther Finance Advisors's Arbutus Biopharma position peaked at $30.8K in Q3 2024.
19 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.